Sangamo to reclaim hemophilia A therapy rights post Pfizer termination

Sangamo Therapeutics

30/12/2024 21:27

Dec 30 (Reuters) - Sangamo Therapeutics  SGMO.O  said on
Monday it would regain full rights to its hemophilia A gene
therapy after co-development partner Pfizer  PFE.N  terminated
the agreement. 

 (Reporting by Puyaan Singh in Bengaluru; Editing by Mohammed
Safi Shamsi)
 ((Puyaan.Singh@thomsonreuters.com;))